Arnoud J Templeton
Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
Neubauer M, Nicolas G, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner-Liewen F, Templeton A, Schäfer N, Wild D, Chirindel A, all investigators on behalf of the SSNM Therapy Working Group. Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging 2023
01.12.2023Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
01.12.2023Eur J Nucl Med Mol Imaging 2023
Neubauer Moritz C, Nicolas Guillaume, Bauman Andreas, Fani Melpomeni, Nitzsche Egbert U, Afshar-Oromieh Ali, Forrer Flavio, Rentsch Cyrill A, Stenner-Liewen Frank, Templeton Arnoud J, Schäfer Niklaus G, Wild Damian, Chirindel Alin, all investigators on behalf of the SSNM Therapy Working Group
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss Med Wkly 2023; 153:40108.
15.08.2023Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
15.08.2023Swiss Med Wkly 2023; 153:40108
Templeton Arnoud J, Omlin Aurelius, Berthold Dominik R, Beyer Jörg, Burger Irene A, Eberli Daniel, Engeler Daniel, Fankhauser Christian Daniel, Fischer Stefanie, Gillessen Silke, Nicolas Guillaume, Kroeze Stephanie G C, Lorch Anja, Müntener Michael, Papachristofilou Alexandros, Schäfer Niklaus G, Seiler Daniel, Stenner-Liewen Frank, Tsantoulis Petros, Vlajnic Tatjana, Zilli Thomas, Zwahlen Daniel Rudolf, Cathomas Richard
Diagnosis and Treatment of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland.
Schlegel T, Hägele-Link S, Bertotto C, Rieger U, Wittchow S, Schlaeppi M, Templeton A. Diagnosis and Treatment of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland. Complement Med Res 2023
16.05.2023Diagnosis and Treatment of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland.
16.05.2023Complement Med Res 2023
Schlegel Tiffany, Hägele-Link Stefan, Bertotto Corrado, Rieger Urte, Wittchow Sophia, Schlaeppi Marc, Templeton Arnoud J
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci 2023; 50:57-60.
20.02.2023The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
20.02.2023Eur Urol Open Sci 2023; 50:57-60
Fischer Stefanie, Rothermundt Christian, Stalder Odile, Terbuch Angelika, Hermanns Thomas, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Seifert Bettina, Alex Kluth Luis, Ufe Mark-Peter, Mingrone Walter, Templeton Arnoud J, Fischer Natalie Fischer, Rothschild Sacha I, Woelky Regina, Gillessen Silke, Cathomas Richard
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Christiansen A, Lobo J, Fankhauser C, Rothermundt C, Cathomas R, Batavia A, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. Front Oncol 2022; 12:1056823.
08.12.2022Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
08.12.2022Front Oncol 2022; 12:1056823
Christiansen Ailsa J, Lobo João, Fankhauser Christian D, Rothermundt Christian, Cathomas Richard, Batavia Aashil A, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Jörg, Hermanns Thomas
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus 2022
12.11.2022Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
12.11.2022Eur Urol Focus 2022
Neuenschwander Anne, Lonati Chiara, Antonelli Luca, Papachristofilou Alexandros, Cathomas Richard, Rothermundt Christian, Templeton Arnoud J, Gulamhusein Aziz, Fischer Stefanie, Gillessen Silke, Hermanns Thomas, Lorch Anja, Mattei Agostino, Fankhauser Christian D
Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R, Tibau A, Molto Valiente C, Seruga B, Ocana A, Amir E, Templeton A. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PloS one 2022; 17:e0268545.
10.06.2022Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
10.06.2022PloS one 2022; 17:e0268545
Adam Roman, Tibau Ariadna, Molto Valiente Consolación, Seruga Bostjan, Ocana Alberto, Amir Eitan, Templeton Arnoud J
Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bührer E, Cathomas R, Fischer N, Hermanns T, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild S, Seifert B, Templeton A, Terbuch A, Ufen M, Woelky R, Gillessen S, Rothermundt C. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022; 40:16-18.
26.04.2022Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
26.04.2022Eur Urol Open Sci 2022; 40:16-18
Pratsinis Manolis, Fankhauser Christian, Pratsinis Katerina, Beyer Jörg, Bührer Emanuel, Cathomas Richard, Fischer Natalie, Hermanns Thomas, Hirschi-Blickenstorfer Anita, Kamradt Jörn, Alex Kluth Luis, Zihler Deborah, Mingrone Walter, Müller Beat, Nestler Tim, Rothschild Sacha I, Seifert Bettina, Templeton Arnoud J, Terbuch Angelika, Ufen Mark-Peter, Woelky Regina, Gillessen Silke, Rothermundt Christian
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Fankhauser C, Christiansen A, Rothermundt C, Cathomas R, Wettstein M, Grossmann N, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer 2021; 126:1140-1144.
15.12.2021Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
15.12.2021Br J Cancer 2021; 126:1140-1144
Fankhauser Christian D, Christiansen Ailsa J, Rothermundt Christian, Cathomas Richard, Wettstein Marian S, Grossmann Nico C, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Joerg, Hermanns Thomas
[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]
Omlin A, Zwahlen D, Wyler S, Wild D, Templeton A, Stenner F, Schmid H, Roggero E, Rentsch C, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer S, Eberli D, Beyer J, Spahn M, Cathomas R. [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]. Praxis (Bern 1994) 2018; 107:1043-1051.
01.09.2018[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]
01.09.2018Praxis (Bern 1994) 2018; 107:1043-1051
Omlin Aurelius, Zwahlen Daniel, Wyler Stephen, Wild Damian, Templeton Arnoud J, Stenner Frank, Schmid Hans-Peter, Roggero Enrico, Rentsch Cyrill A, Nitzsche Egbert, Kueng Marc, Jochum Wolfram, Gillessen Sommer Silke, Eberli Daniel, Beyer Jörg, Spahn Martin, Cathomas Richard
Vitamin D levels in Swiss breast cancer survivors
Baumann M, Templeton A, Ruhstaller T, Riesen W, Mark M, Klingbiel D, Hochstrasser A, Dietrich D, Dani S, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly 2018; 148:w14576.
29.01.2018Vitamin D levels in Swiss breast cancer survivors
29.01.2018Swiss Med Wkly 2018; 148:w14576
Baumann Michael, Templeton Arnoud J, Ruhstaller Thomas, Riesen Walter F, Mark Michael Thomas, Klingbiel Dirk, Hochstrasser Andreas, Dietrich Daniel, Dani Sergio Ulhoa, Thürlimann Beat
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
24.07.2017Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
24.07.2017Lung Cancer 2017; 111:176-181
Diem Stefan, Schmid Sabine, Krapf Mirjam, Flatz Lukas, Born Diana, Jochum Wolfram, Templeton Arnoud J, Früh Martin
Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression.
Adam R, Diez-Gonzalez L, Ocana A, Seruga B, Amir E, Templeton A. Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. Exp Mol Pathol 2017; 102:455-474.
12.05.2017Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression.
12.05.2017Exp Mol Pathol 2017; 102:455-474
Adam Roman, Diez-Gonzalez Laura, Ocana Alberto, Seruga Bostjan, Amir Eitan, Templeton Arnoud J
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC cancer 2013; 13:153.
25.03.2013Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
25.03.2013BMC cancer 2013; 13:153
Templeton Arnoud J, Thürlimann Beat, Baumann Michael, Mark Michael, Stoll Sarah, Schwizer Madeleine, Dietrich Daniel, Ruhstaller Thomas